We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

118 hedge funds and large institutions have $114M invested in Ventyx Biosciences in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 44 increasing their positions, 30 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 30

9% more call options, than puts

Call options by funds: $314K | Put options by funds: $288K

6% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 18

1% more funds holding

Funds holding: 117118 (+1)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

6.95% less ownership

Funds ownership: 81.21%74.26% (-6.9%)

13% less capital invested

Capital invested by funds: $132M → $114M (-$17.8M)

Holders
118
Holders Change
+1
Holders Change %
+0.85%
% of All Funds
1.69%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
19
Increased
44
Reduced
30
Closed
18
Calls
$314K
Puts
$288K
Net Calls
+$26K
Net Calls Change
+$252K
Name Holding Trade Value Shares
Change
Change in
Stake
DM
1
Deerfield Management
New York
$14.6M +$2.04M +885,931 +15%
BlackRock
2
BlackRock
New York
$10.7M +$321K +139,740 +3%
Citadel Advisors
3
Citadel Advisors
Florida
$9.71M -$3M -1,303,384 -23%
Vanguard Group
4
Vanguard Group
Pennsylvania
$7.56M +$1.09M +473,479 +16%
FCM
5
Farallon Capital Management
California
$6.91M
TCM
6
Tang Capital Management
California
$6.76M
OCA
7
Octagon Capital Advisors
New York
$5.21M
RG
8
Redmile Group
California
$4.59M -$131K -56,911 -3%
SCM
9
Sio Capital Management
New York
$4.3M +$2.74M +1,193,024 +153%
Goldman Sachs
10
Goldman Sachs
New York
$4.22M +$1.09M +475,899 +33%
VPC
11
Vestal Point Capital
New York
$3.76M +$943K +410,000 +31%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$3.03M +$178K +77,350 +6%
UBS Group
13
UBS Group
Switzerland
$2.61M +$2.7M +1,175,766 +5,438%
State Street
14
State Street
Massachusetts
$2.59M +$22.5K +9,783 +0.8%
SFM
15
Sphera Funds Management
Israel
$2.21M
JP Morgan Chase
16
JP Morgan Chase
New York
$2.2M +$46.5K +20,236 +2%
Bank of America
17
Bank of America
North Carolina
$1.96M +$1.11M +483,862 +117%
Jacobs Levy Equity Management
18
Jacobs Levy Equity Management
New Jersey
$1.24M +$213K +92,753 +19%
Charles Schwab
19
Charles Schwab
California
$1.06M +$41.2K +17,898 +4%
Northern Trust
20
Northern Trust
Illinois
$1.02M +$165K +71,622 +18%
Two Sigma Advisers
21
Two Sigma Advisers
New York
$1.01M +$580K +252,400 +118%
Connor, Clark & Lunn Investment Management (CC&L)
22
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.01M +$98K +42,600 +10%
WC
23
Wexford Capital
Florida
$979K
SSA
24
Schonfeld Strategic Advisors
New York
$943K -$1.66M -721,241 -63%
Macquarie Group
25
Macquarie Group
Australia
$937K

VTYX Hedge Fund Activity: Q3 2024 in Review

118 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q3 2024, worth a combined $114M — down 13% from $132M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new VTYX positions and 18 closed out — a net gain of 1 holder — while 44 added to existing stakes and 30 trimmed.

The largest buyer was Sio Capital Management, adding an estimated $2.74M. The largest seller was Capital International Investors, exiting entirely with an estimated $12.1M sold.

  • 118 institutional investors held Ventyx Biosciences (VTYX) as of Q3 2024, up from 117 in Q2 2024.
  • Funds reported $114M of Ventyx Biosciences stock for Q3 2024, down 13% quarter-over-quarter.
  • 19 funds opened new Ventyx Biosciences positions in Q3 2024 and 18 closed out, a net change of +1 holder.
  • The largest Ventyx Biosciences buyer in Q3 2024 was Sio Capital Management, an estimated $2.74M added.
  • The largest Ventyx Biosciences seller in Q3 2024 was Capital International Investors, an estimated $12.1M sold.

Based on aggregated 13F filings for Q3 2024.